[
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The PRISMA flowchart (Figure 1) outlines the process and shows the combined original and new numbers (Moher 2009).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The most common source of potential bias was selection bias because 30 of the 61 studies either did not adjust for potential confounding factors or failed to adjust for all of the major variables associated with a particular outcome (Figure 2 and Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Attrition bias was of concern in only 13 studies (Altschuler 2008;Brandberg 2008;Gahm 2010; Geiger 2007; Gopie 2013;Hopwood 2000;Leis 1981;Metcalfe 2004b;Metcalfe 2005;Montgomery 1999; Pennisi 1989; Skytte 2011) (Figure 2) and unclear in two additional studies (Bedrosian 2010;Metcalfe 2014), as most studies accounted for all the participants in the initial sample they specified.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomyBRCA1 and BRCA2 mutations\nTwo studies reported on women with BRCA1/2 mutations.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants\n\n\n\nOpen in a new tab\nBRRSO: bilateral risk‐reducing salpingo‐oophorectomy \nBRRM: bilateral risk‐reducing mastectomy \nCI: confidence interval \nCRRM: contralateral risk‐reducing mastectomy \nHR: hazard ratio \nLCIS: lobular carcinoma in situ \nRR: relative risk \nRRM: risk‐reducing mastectomy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This is not statistically significantly different to the BRRM rate (P = 0.23)(Figure 1 shows the Kaplan‐Meier curve for disease‐free survival.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the Kaplan Meier curve for disease‐free survival for CRRM vs BRRM in the paper)\nMedian follow‐up = 22 yearsRange = 3‐34 years\nNone\n \n\n\n\nPennisi 1989BRRM and CRRM combined\nBRRM/CRRM: 3 of the 1500 participants died from BCNo comparison group\n70% followed for 9 years\n30% were lost to follow‐up\n1500 patients from 165 plastic surgeons who had subcutaneous RRM and were registered with the Subcutaneous Mastectomy Data Evaluation Center78 (5.2%) participants had obscure carcinoma and 51 (3.4%) had LCIS at the time of surgery and were included in the study.Among the 139 participants who had CRRM, 4 (3%) had BC and 5 (3.6%) had LCIS and were included in the study.300 (20%) had a 1st‐degree relative with BC and 21% had a history of 2nd‐degree maternal or paternal relatives with a history of BC.Skin necrosis occurred in 5% of the participants.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chung 2012CRRM\n\nSummary result: CRRM was not a significant predictor of overall survival, disease‐free survival, distant metastasis‐free survival, or local recurrence‐free survivalSee Figure 2 (in paper) for the 4 Kaplan‐Meier survival curvesOverall survival curve difference P = 0.415Disease‐free survival curve difference P = 0.081Local recurrence‐free survival curve difference P = 0.225Distant metastasis‐free survival curve difference P = 0.417Participants had unilateral Stage 0‐III BC\nMedian follow‐up = 61 months\nNone\nAll‐patients adjusted model: adjusted for stage, nuclear grade, hormone receptor status, and chemotherapy historyAll‐patients matched model: matched by propensity score.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Evans 2013CRRM\nAll deaths: CRRM = 9/105; controls = 180/473Deaths from BC: CRRM = 8/105; controls = 150/473Other deaths: CRRM = 0; controls = 1010 year survival (%):CRRM and BRRSO = 92% (HR 0.16, 95% CI 0.06‐0.44)CRRM no BRRSO = 83% (HR 0.48, 95% CI 0.19‐1.14)BRRSO no CRRM = 81% (HR 0.46, 95% CI 0.27‐0.78)No surgery = 65% (no HR)Figure 2 shows the survival curves for CRRM vs no‐CRRM groups.Adjusted analysis: \"After adjusting for potential confounders only CRRM (HR 0.28, 95% CI 0.14 to 0.55) and BRRSO (HR 0.34, 95% CI 0.21 to 0.55) were independently predictive of improved survival.\" Table 2 shows the detailed results for CRRM vs no‐CRRM groupingsCRRM group: all deaths = 9; deaths from BC = 8; deaths other = 1; 10‐year survival = 89%Control group: all deaths = 26; deaths from BC = 24; other deaths = 210‐year survival = 71%.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the survival curves for CRRM vs no CRRM for BRCA1/2 mutation carriers.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cox analysis yielded an HR 0.49 (95% CI 0.29 to 0.82) adjusted for BRRSO10‐year survival: fewer women died in the CRRM group (8% vs 19%, P < 0.001)15‐year survival: better in the CRRM group (86%) than in the control group (74%)Survival curves (Kaplan‐Meier) are shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Death by all causes favored CRRM (P logrank < 0.119) but not statistically significantly.Figure 2 (in paper) shows the survival curves.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 (in paper) shows the stratified HR.All of the participants in this study were BRCA1/2 positive\nMedian follow‐up for CRRM = 11.4 yearsMedian follow‐up for control = 11.3 years\nNone\nThere is a lack of data on BC‐specific mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "19%‐36%)(P=0.01).15‐year all‐cause survivalCRRM group 64% (41/64) (95% CI 45% to 78%)No‐CRRM group 49% (87/182) (95% CI 39% to 58%)P = 0.2615‐year disease‐specific survival in women with Stage 0, I or II BCCRRM group 71% (45/64) (95% CI 52% to 84%)No CRRM (surveillance) 53% (96/182) (95% CI 42% to 62%)P = 0.06\nMedian \n6.2 years for CRRM group6.8 years for no‐CRRM group\nNone\nComparison group participants were matched for age, stage of disease at diagnosis, presence of LCIS, chemotherapy and tamoxifen therapy from among 2852 participants who underwent mastectomy between 1 January 1973 and 30 September 1998 at 1 institution.71% having CRRM had immediate reconstruction\n\n\n\nPesce 2014CRRM\nCRRM had better survival than unilateral mastectomy, without adjustments (P < 0.001)Unadjusted Kaplan‐Meier survival curve showed CRRM was statistically significantly better than unilateral mastectomy (P = 0.0002). (Figure 1 in the paper)There was no statistically significant difference inoverall survival between CRRM and unilateral mastectomy after adjusting for various factors.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "See Figure 3 in the paper.Unadjusted Kaplan‐Meier survival curve showed no difference between groups for ER‐negative patients (P = 0.432). (Figure 2 in the paper)\nMedian follow‐up = 6.1 years\nNone\n \n\n\n\nVan Sprundel 2005CRRM\n\nAll‐cause mortality in BRCA1/2 carriers \nCRRM survival = 94% \nSurveillance group survival = 77% \nP = 0.03BC mortality in BRCA1/2 carriers \nBC‐specific survival was not significantly better in the CRRM group without BRRSO P = 0.11)Participants who had CRRM and BRRSO had significantly better survival than those who did not have BRRSO: \nall‐cause survival: HR 0.12 (95% CI 0.03 to 0.46) \nBC survival: HR 0.16 (95% CI 0.04 to 0.61)\nMean = 3.5 years\nNone\nSignificant overall survival advantage in CRRM group mostly due to higher mortality related to primary BC and ovarian cancer in surveillance groupCRRM effect on overall survival not significant in participants who had BRRSO after adjustment for BRRSO; only BRRSO led to significant improvement of overall survival\n\n\n\nZeichner 2014CRRM\n237 participants < 40 years with BC, 42 CRRM, 195 no CRRM.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]